Matthew D. Blagys

Interaction of therapeutic process and alliance during psychological assessment.

Utilizing a collaborative therapeutic assessment (TA) model proposed by Finn and Tonsager (1997), we examined the interaction between therapeutic alliance and in-session process during the assessment phase of treatment. This study compares the utility of the TA model (n = 38) versus a traditional information gathering model (n = 90) of assessment. The results of this study indicate that the use of a TA model may decrease the number of patients who terminate treatment against medical advice. The Session Evaluation Questionnaire (Stiles & Snow, 1984), Combined Alliance Short Form (Hatcher & Barends, 1996), and Penn Helping Alliance Questionnaire-Revised (Barber & Crits-Christoph, 1996) can reliably measure the patients experience of the assessment. The psychological assessment process may impact the patients experience of assessment feedback and aid in the development of a therapeutic alliance. The therapeutic alliance developed during the assessment was found to be related to alliance early in psychotherapy. We discuss the theoretical, clinical, and research implications of these findings.

Evaluating the Phase Model of Change During Short-Term Psychodynamic Psychotherapy

This study examined the phase model of psychotherapy change (Howard, Lueger, Maling, & Martinovich, 1993; Howard, Moras, Brill, Martinovich, & Lutz, 1996) and assessed the domains of subjective well-being, symptomatic distress, and social/interpersonal functioning during short-term psychodynamic psychotherapy. Specifically, we assessed evaluation/third-session to ninth-session changes in a group of 20 treated patients. These three domains were examined for both statistical and clinically significant change (Jacobson & Truax, 1991). Treatment fidelity and credibility were also evaluated. Statistical and clinically significant improvement in the domains of subjective well-being and symptom distress were evident by the ninth session of short-term dynamic psychotherapy. Statistical and reliable improvement were observed in relational functioning during the same time period. In addition, changes in both subjective well-being and symptomatic distress contributed unique and separate variance to predicting changes in social/interpersonal functioning. The results with respect to the differential effects predicted by the phase model of change during the early course of treatment are discussed.

short-term Psychodynamic Psychotherapy for Depression: An Examination of Statistical, Clinically Significant, and Technique-specific Change

Abstract This study investigates the effectiveness of short‐term psychodynamic psychotherapy (STPP) for depression in a naturalistic setting utilizing a hybrid effectiveness/efficacy treatment research model. Twenty‐one patients were assessed pre‐ and post‐treatment through clinician ratings and patient self‐report on scales representing specific DSM‐IV depressive, global symptomatology, relational, social, and occupational functioning. Treatment credibility, fidelity, and satisfaction were examined, all of which were found to be high. All areas of functioning assessed exhibited significant and positive changes. These adaptive changes in functioning demonstrated large statistical effects. Likewise, changes in depressive symptoms evaluated at the patient level utilizing clinical significance methodology were found to be high. A significant direct process/outcome link between STPP therapist techniques and changes in depressive symptoms was observed. Alternative treatment interventions within STPP were evaluated in relation to subsequent improvements in depression and were found to be nonsignificant. The present results demonstrate that robust statistical and clinically significant improvement can occur in a naturalistic/hybrid model of outpatient STPP for depression.

Personality and symptom change in treatment-refractory inpatients: evaluation of the phase model of change using Rorschach,TAT, and DSM-IV Axis V.

In this study, we examined global treatment outcomes during 16 months of intensive, psychodynamic treatment for 77 inpatients suffering from treatment-refractory disorders. Hypotheses based on the phase model of treatment change (Howard, Lueger, Maling, & Martinovich, 1993; Howard, Moras, Brill, Martinovich, & Lutz, 1996) were supported in the study results. Diagnostic and Statistical Manual of Mental Disorders (4th ed.; American Psychiatric Association, 1994) Axis V scales assessing behavioral functioning demonstrated large and medium effect size change, whereas stable, enduring personality functioning assessed by psychoanalytic Rorschach scales and the Social Cognition and Object Relations Scale (Westen, 1995) for the Thematic Apperception Test (Murray, 1943) demonstrated small and medium effect size change. We also report assessment of reliable change index and clinical significance. The ecological validity of Rorschach measures is supported by significant validity coefficients (in the hypothesized directions) between implicit measures of personality functioning and behavioral ratings.

Development and Initial Validation of a Brief Symptom Measure

UNLABELLED Self-report measures of psychiatric symptomatology are important components of treatment monitoring and service evaluation programs. However, the currently available measures have numerous limitations including being symptom or disorder specific, suited to a limited range of clinical settings, and having excessive burden. Consequently, there is a need for a brief and psychometrically robust measure of global symptomatology that is applicable across diverse clinical settings, therapeutic modalities and patient populations. This paper presents the development and initial validation of such a scale, the Brief Symptom Measure-25 (BSM-25). We report findings from multiple samples examining the reliability, validity, sensitivity to change and factor structure of the new instrument. The results suggest that the BSM-25 has good reliability, is suitable to multiple levels of care, sensitive to treatment induced change and has promising validity. Exploratory bifactor modelling revealed that all items loaded strongly on a general factor (bifactor) while also forming two minor group factors. Potential limitations of this study along with future research and clinical applications of the BSM-25 are discussed. KEY PRACTITIONER MESSAGE The BSM-25 is a broad measure of symptom severity that is easy to administer and score, appropriate for divers patient populations, and suitable for monitoring progress in routine clinical practice.